Insider Purchases: Inside the Buy
Tag: value investing
🥑 Mission Produce (AVO) Stock Analysis: Why Insiders Just Bought $7.9 Million of Stock
Mission Produce's directors recently deployed nearly $7.9 million of personal capital into AVO shares. Combined with the Calavo acquisition, a fresh $100 million buyback, and a move into higher-margin prepared foods, the avocado giant may be entering a new chapter.
🏝️ The 125% Float Monopoly: Inside Oxford Industries' High-Conviction Floor and the 8-Day Island Squeeze
With insiders buying, institutions owning more than the float itself, a 7.5% dividend yield and Tommy Bahama still thriving, Oxford Industries presents one of the more unusual setups in retail.
🦅 Erie Indemnity (ERIE): The Hidden Fee Castle Behind an 11-Day Short Squeeze Setup
Erie Indemnity isn't a traditional insurer. It collects fees rather than assuming most underwriting risk, creating one of the most unique business models in financial services. After a rare $1.4 million insider purchase, a 59% decline from all-time highs, and nearly 12 days-to-cover short interest, investors may want another look at this Dividend Aristocrat.
🍩 Krispy Kreme (DNUT): The 3G Mastermind, 7-Day Squeeze Trap, and the Great Post-IPO Cash Flow Resuscitation
Krispy Kreme shares remain down more than 80% from their highs, but insiders—including former 3G Capital executive Bernardo Hees—are buying aggressively. With free cash flow finally turning positive and margins improving, the iconic doughnut maker may be entering a new chapter.
🚢 Norwegian Cruise Line (NCLH): Why Insiders Just Bought $27M of Stock
Norwegian Cruise Line Holdings may be more than a cruise recovery stock. With a new CEO, nearly $27 million in insider purchases, institutional ownership locking up almost the entire float, and valuation metrics that look surprisingly cheap, NCLH is turning into one of the more intriguing turnaround stories on deck.
🫀 Boston Scientific (BSX): A GARP Reset on a Medical Device Powerhouse
Boston Scientific stock has fallen nearly 48% from its highs, but the business engine remains strong. With double-digit revenue growth, major cardiovascular catalysts, director insider buying, low short interest, and a $2B buyback, BSX may be one of the cleaner large-cap healthcare GARP setups on the market.
🚪 Fortune Brands (FBIN): Activist Capital Just Kicked the Door Open
Fortune Brands Innovations (FBIN) is under pressure from weak housing demand, shrinking profits, and leadership uncertainty. But while Wall Street hesitates, activist investor Ed Garden just made a massive $13.6 million insider purchase. Is this a value trap… or a smart-home turnaround hiding in plain sight?
🥚 Vital Farms (VITL): The Great Egg Glut of 2026
Vital Farms stock has been absolutely scrambled by the 2026 egg glut, plunging more than 80% from its highs as profitability collapsed and short sellers flooded the farm. But coordinated insider buying, a debt-free balance sheet, and extreme institutional ownership suggest the setup may be far more explosive than the market currently realizes.
🐟 Nomad Foods (NOMD): The Frozen Food Giant Trading Like a Distressed Stock
Nomad Foods may not be sexy, but Europe’s frozen-food empire is suddenly attracting serious insider buying, quant fund interest, and deep-value investors. With a near-7% dividend yield, aggressive buybacks, and a forward P/E near 5x, NOMD might be one of the market’s coldest contrarian opportunities.
🐾 Zoetis (ZTS): A Premium Veterinary Titan Sitting in the Doghouse
Zoetis (ZTS) may be one of the most interesting “quality in the doghouse” setups of 2026. The global animal-health leader is still profitable, institutionally loved, and backed by powerful pet-humanization trends — yet soft U.S. pet spending, competition, and lowered guidance have crushed the stock. With directors buying near the lows and forward P/E near 11x, is ZTS finally becoming a value play?